Related Experiment Videos
[Fabry disease in Italy: first epidemiologic and collaborative study].
Roberta Ricci1, Mario Castorina, Mariangela Di Lillo
1Dipartimento di Scienze Pediatriche Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore di Roma. r.ricci@rm.unicatt.it
Annali Italiani Di Medicina Interna : Organo Ufficiale Della Societa Italiana Di Medicina Interna
|February 1, 2005
Summary
This study defines Fabry disease prevalence in Italy, identifying key early signs for timely diagnosis. Early enzyme replacement therapy can prevent severe complications and improve patient outcomes.
Area of Science:
- Genetics and rare diseases
- Metabolic disorders
- Lysosomal storage diseases
Context:
- Fabry disease is a severe X-linked inherited metabolic disorder.
- Caused by alpha-galactosidase A deficiency, leading to progressive organ damage.
- Often misdiagnosed due to varied clinical presentations.
Purpose:
- To determine the prevalence and incidence of Fabry disease in Italy.
- To describe the natural history and identify early clinical manifestations.
- To facilitate earlier diagnosis and treatment initiation.
Summary:
- A collaborative Italian study identified 65 Fabry disease patients.
- Analyzed patient demographics, age, sex, and onset of symptoms.
- This research highlights clinical signs for accurate early diagnosis.
Impact:
- Early diagnosis through recognized clinical signs is crucial.
- Enzyme replacement therapy can prevent renal and cardiac failure.
- Timely treatment improves quality of life and life expectancy for Fabry patients.